drugset / Trial / NCT00999518

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

NCT00999518

Phase 2 Terminated 205 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this study, the hypothesis being tested is that tanezumab will show efficacy at several doses on reducing pain with sufficient tolerability. Tanezumab's safety will also be assessed at different dose levels

Timeline

Start
2010-01-22
Primary completion
2010-11-17
Completion
2011-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 1 mg Subcutaneous
Subject Tanezumab Monoclonal antibody 2.5 mg Subcutaneous
Subject Tanezumab Monoclonal antibody 10 mg Subcutaneous
Subject Tanezumab Monoclonal antibody 20 mg Subcutaneous

Indications